EP2557164A1
(en)
|
2003-02-18 |
2013-02-13 |
Kevin M. Slawin |
Induced activation in dendritic cells
|
WO2010049935A1
(en)
|
2008-10-30 |
2010-05-06 |
Yeda Research And Development Co. Ltd. |
Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
|
US10323236B2
(en)
|
2011-07-22 |
2019-06-18 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
US20140212398A1
(en)
|
2011-09-08 |
2014-07-31 |
Yeda Research And Development Co. Ltd. |
Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
|
US9458450B2
(en)
|
2012-03-15 |
2016-10-04 |
Flodesign Sonics, Inc. |
Acoustophoretic separation technology using multi-dimensional standing waves
|
US10322949B2
(en)
|
2012-03-15 |
2019-06-18 |
Flodesign Sonics, Inc. |
Transducer and reflector configurations for an acoustophoretic device
|
US10704021B2
(en)
|
2012-03-15 |
2020-07-07 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
US9752113B2
(en)
|
2012-03-15 |
2017-09-05 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
US9950282B2
(en)
|
2012-03-15 |
2018-04-24 |
Flodesign Sonics, Inc. |
Electronic configuration and control for acoustic standing wave generation
|
US10689609B2
(en)
|
2012-03-15 |
2020-06-23 |
Flodesign Sonics, Inc. |
Acoustic bioreactor processes
|
US9745548B2
(en)
|
2012-03-15 |
2017-08-29 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
US10967298B2
(en)
|
2012-03-15 |
2021-04-06 |
Flodesign Sonics, Inc. |
Driver and control for variable impedence load
|
ES2659217T3
(es)
|
2012-03-28 |
2018-03-14 |
Gadeta B.V. |
Intercambio combinatorio de cadena receptora de célula T gamma 9 delta 2
|
US10737953B2
(en)
|
2012-04-20 |
2020-08-11 |
Flodesign Sonics, Inc. |
Acoustophoretic method for use in bioreactors
|
US20150017136A1
(en)
*
|
2013-07-15 |
2015-01-15 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotherapy
|
PL2855667T3
(pl)
*
|
2012-05-25 |
2024-03-25 |
Cellectis |
Sposoby uzyskiwania metodami inżynierii allogenicznych i opornych na immunosupresję limfocytów t do immunoterapii
|
RU2019143431A
(ru)
*
|
2012-11-01 |
2020-04-28 |
Фэктор Байосайенс Инк. |
Способы и продукты для экспрессии белков в клетках
|
WO2014093709A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
SG10201912328UA
(en)
|
2012-12-12 |
2020-02-27 |
Broad Inst Inc |
Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
|
CN104995302B
(zh)
|
2013-01-16 |
2021-08-31 |
爱默蕾大学 |
Cas9-核酸复合物及其相关用途
|
US9499855B2
(en)
|
2013-03-14 |
2016-11-22 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
AU2014236726A1
(en)
*
|
2013-03-14 |
2015-09-17 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlling T cell proliferation
|
US9587237B2
(en)
|
2013-03-14 |
2017-03-07 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
US11311575B2
(en)
*
|
2013-05-13 |
2022-04-26 |
Cellectis |
Methods for engineering highly active T cell for immunotherapy
|
CA2912375C
(en)
*
|
2013-05-13 |
2023-03-14 |
Cellectis |
Methods for engineering highly active t cell for immunotherapy
|
AU2014281028B2
(en)
|
2013-06-17 |
2020-09-10 |
Massachusetts Institute Of Technology |
Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy
|
WO2014204725A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
EP3725885A1
(en)
|
2013-06-17 |
2020-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
EP3011034B1
(en)
|
2013-06-17 |
2019-08-07 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
|
WO2014204724A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
MX365218B
(es)
|
2013-09-06 |
2019-05-27 |
Aurigene Discovery Tech Ltd |
Derivados de 1,2,4-oxadiazol como inmunomoduladores.
|
EA031325B1
(ru)
|
2013-09-06 |
2018-12-28 |
Ауриген Дискавери Текнолоджиз Лимитед |
Циклические пептидомиметические соединения в качестве иммуномодуляторов
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
CU24345B1
(es)
|
2013-09-06 |
2018-05-08 |
Aurigene Discovery Tech Ltd |
Derivados de 1,3,4-oxadiazol y 1,3,4-tiadiazol como inmunomoduladores
|
US9745569B2
(en)
|
2013-09-13 |
2017-08-29 |
Flodesign Sonics, Inc. |
System for generating high concentration factors for low cell density suspensions
|
WO2015070083A1
(en)
|
2013-11-07 |
2015-05-14 |
Editas Medicine,Inc. |
CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS
|
EP3071686B1
(en)
*
|
2013-11-22 |
2020-07-22 |
Cellectis SA |
Method for generating batches of allogeneic t-cells with averaged potency
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
JP6943568B2
(ja)
*
|
2013-12-06 |
2021-10-06 |
アメリカ合衆国 |
胸腺間質性リンパ球新生因子受容体特異的キメラ抗原受容体及びそれを使用する方法
|
CN111206032A
(zh)
|
2013-12-12 |
2020-05-29 |
布罗德研究所有限公司 |
用于基因组编辑的crispr-cas***和组合物的递送、用途和治疗应用
|
US9840699B2
(en)
|
2013-12-12 |
2017-12-12 |
President And Fellows Of Harvard College |
Methods for nucleic acid editing
|
EP3080271B1
(en)
|
2013-12-12 |
2020-02-12 |
The Broad Institute, Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
CA2932472A1
(en)
|
2013-12-12 |
2015-06-18 |
Massachusetts Institute Of Technology |
Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
|
WO2015095811A2
(en)
|
2013-12-20 |
2015-06-25 |
The Board Institute Inc. |
Combination therapy with neoantigen vaccine
|
WO2015105955A1
(en)
|
2014-01-08 |
2015-07-16 |
Flodesign Sonics, Inc. |
Acoustophoresis device with dual acoustophoretic chamber
|
CA2937750A1
(en)
*
|
2014-02-14 |
2015-08-20 |
Bellicum Pharmaceuticals, Inc. |
Methods for activating t cells using an inducible chimeric polypeptide
|
EP3800248A3
(en)
*
|
2014-04-18 |
2021-08-04 |
Editas Medicine, Inc. |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
MX370018B
(es)
*
|
2014-04-25 |
2019-11-28 |
Bluebird Bio Inc |
Metodos mejorados para la elaboracion de terapias celulares adoptivas.
|
BR112016024481A2
(pt)
|
2014-04-25 |
2017-10-10 |
Bluebird Bio Inc |
receptores quiméricos de antígenos com promotor mnd
|
WO2015167766A1
(en)
|
2014-04-29 |
2015-11-05 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Ccr5 disruption of cells expressing anti-hiv chimeric antigen receptor (car) derived from broadly neutralizing antibodies
|
GB201407852D0
(en)
|
2014-05-02 |
2014-06-18 |
Iontas Ltd |
Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
|
WO2015179540A1
(en)
*
|
2014-05-20 |
2015-11-26 |
Regents Of The University Of Minnesota |
Method for editing a genetic sequence
|
SI3151672T1
(sl)
|
2014-06-06 |
2021-03-31 |
Bluebird Bio, Inc. |
Izboljšani T-celični sestavki
|
US9744483B2
(en)
|
2014-07-02 |
2017-08-29 |
Flodesign Sonics, Inc. |
Large scale acoustic separation device
|
US10738278B2
(en)
|
2014-07-15 |
2020-08-11 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
WO2016014725A1
(en)
|
2014-07-22 |
2016-01-28 |
The University Of Notre Dame Du Lac |
Molecular constructs and uses thereof
|
US10752668B2
(en)
|
2014-07-25 |
2020-08-25 |
Theravectys |
Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
|
EP3177718B1
(en)
|
2014-07-30 |
2022-03-16 |
President and Fellows of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
MY189028A
(en)
*
|
2014-08-19 |
2022-01-20 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
WO2016036746A1
(en)
|
2014-09-02 |
2016-03-10 |
Bellicum Pharmaceuticals, Inc. |
Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
|
WO2016054520A2
(en)
*
|
2014-10-03 |
2016-04-07 |
The California Institute For Biomedical Research |
Engineered cell surface proteins and uses thereof
|
MA41538A
(fr)
*
|
2014-10-17 |
2017-12-26 |
Baylor College Medicine |
Cellules immunitaires bipartites et tripartites de signalisation
|
EP3215168B1
(en)
*
|
2014-10-31 |
2023-08-02 |
The Trustees of the University of Pennsylvania |
Altering gene expression in modified t cells and uses thereof
|
AU2015348198A1
(en)
*
|
2014-11-20 |
2017-06-08 |
Umc Utrecht Holding B.V. |
Use of antibodies for enrichment of engineered T cells with exogenous immune receptors and antibodies for use in depletion of engineered T cells
|
US10201606B2
(en)
|
2014-11-26 |
2019-02-12 |
Miltenyi Biotec Gmbh |
Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
|
GB201421096D0
(en)
*
|
2014-11-27 |
2015-01-14 |
Imp Innovations Ltd |
Genome editing methods
|
US20170362580A1
(en)
|
2014-12-12 |
2017-12-21 |
James Zhu |
Methods and compositions for selectively eliminating cells of interest
|
BR112017012502B1
(pt)
|
2014-12-12 |
2020-09-15 |
Bluebird Bio, Inc. |
Polinucleotídeo, polipeptídeo de car codificado pelo dito polinucleotídeo, vetor compreendendo o dito polinucleotídeo, composição compreendendo o dito vetor e método para geração de uma célula imune efetora compreendendo um car
|
EP3889260A1
(en)
|
2014-12-12 |
2021-10-06 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
WO2016100975A1
(en)
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
EP3757211A1
(en)
|
2014-12-19 |
2020-12-30 |
The Broad Institute, Inc. |
Methods for profiling the t-cell-receptor repertoire
|
EP4134430A1
(en)
|
2015-02-06 |
2023-02-15 |
National University of Singapore |
Methods for enhancing efficacy of therapeutic immune cells
|
EP3089761B1
(en)
*
|
2015-03-02 |
2019-06-12 |
Innovative Cellular Therapeutics Co., Ltd. |
Reducing immune tolerance induced by pd l1
|
CN107427477B
(zh)
|
2015-03-10 |
2021-11-26 |
奥瑞基尼探索技术有限公司 |
作为免疫调节剂的1,2,4-噁二唑和噻二唑化合物
|
US9777064B2
(en)
*
|
2015-03-17 |
2017-10-03 |
Chimera Bioengineering, Inc. |
Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof
|
ES2926467T3
(es)
|
2015-04-13 |
2022-10-26 |
Maxcyte Inc |
Métodos y composiciones para la modificación del ADN genómico
|
ES2836273T3
(es)
|
2015-04-27 |
2021-06-24 |
Cancer Research Tech Ltd |
Método para el tratamiento del cáncer
|
US11021699B2
(en)
|
2015-04-29 |
2021-06-01 |
FioDesign Sonics, Inc. |
Separation using angled acoustic waves
|
US11708572B2
(en)
|
2015-04-29 |
2023-07-25 |
Flodesign Sonics, Inc. |
Acoustic cell separation techniques and processes
|
US11377651B2
(en)
|
2016-10-19 |
2022-07-05 |
Flodesign Sonics, Inc. |
Cell therapy processes utilizing acoustophoresis
|
JP6890830B2
(ja)
*
|
2015-05-01 |
2021-06-23 |
ベイラー カレッジ オブ メディスンBaylor College Of Medicine |
Ctla−4アンタゴニストによる、免疫応答の増強方法
|
JP2018515139A
(ja)
|
2015-05-08 |
2018-06-14 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
万能ドナー幹細胞および関連する方法
|
KR20180010229A
(ko)
|
2015-05-20 |
2018-01-30 |
더 브로드 인스티튜트, 인코퍼레이티드 |
공유 신생항원
|
EP3298131B1
(en)
|
2015-05-20 |
2023-04-26 |
The Regents of The University of California |
Method for generating human dendritic cells for immunotherapy
|
MX2017015239A
(es)
|
2015-05-29 |
2018-02-19 |
Juno Therapeutics Inc |
Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
|
EP3310932B1
(en)
*
|
2015-06-17 |
2023-08-30 |
The UAB Research Foundation |
Crispr/cas9 complex for genomic editing
|
AU2016278959A1
(en)
*
|
2015-06-17 |
2018-01-18 |
The Uab Research Foundation |
CRISPR/Cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
CN109536474A
(zh)
|
2015-06-18 |
2019-03-29 |
布罗德研究所有限公司 |
降低脱靶效应的crispr酶突变
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
US20170014449A1
(en)
*
|
2015-07-13 |
2017-01-19 |
Elwha LLC, a limited liability company of the State of Delaware |
Site-specific epigenetic editing
|
CA2991301A1
(en)
*
|
2015-07-13 |
2017-01-19 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
US20170020922A1
(en)
*
|
2015-07-16 |
2017-01-26 |
Batu Biologics Inc. |
Gene editing for immunological destruction of neoplasia
|
US10933124B2
(en)
*
|
2015-07-16 |
2021-03-02 |
Yeda Research And Development Co. Ltd. |
Methods of transplantation and disease treatment
|
US11474085B2
(en)
|
2015-07-28 |
2022-10-18 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
US11459540B2
(en)
|
2015-07-28 |
2022-10-04 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
EP3971284B1
(en)
*
|
2015-07-29 |
2023-11-08 |
ONK Therapeutics Limited |
Modified natural killer cells and natural killer cell lines having increased cytotoxicity
|
US10166255B2
(en)
*
|
2015-07-31 |
2019-01-01 |
Regents Of The University Of Minnesota |
Intracellular genomic transplant and methods of therapy
|
CA2997912A1
(en)
*
|
2015-09-09 |
2017-03-16 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Genetic engineering of macrophages for immunotherapy
|
GB201516047D0
(en)
|
2015-09-10 |
2015-10-28 |
Cancer Rec Tech Ltd |
Method
|
US20190255107A1
(en)
|
2015-10-09 |
2019-08-22 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
MX2018004546A
(es)
|
2015-10-16 |
2019-04-15 |
Univ Columbia |
Composiciones y métodos para la inhibicion de antígenos específicos de linaje.
|
EP3365356B1
(en)
|
2015-10-23 |
2023-06-28 |
President and Fellows of Harvard College |
Nucleobase editors and uses thereof
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
EP3368689B1
(en)
|
2015-10-28 |
2020-06-17 |
The Broad Institute, Inc. |
Composition for modulating immune responses by use of immune cell gene signature
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
AU2016343682A1
(en)
|
2015-10-30 |
2018-06-14 |
The Regents Of The University Of California |
Methods of generating T-cells from stem cells and immunotherapeutic methods using the T-cells
|
SG11201803701YA
(en)
*
|
2015-11-04 |
2018-06-28 |
Univ Pennsylvania |
Methods and compositions for gene editing in hematopoietic stem cells
|
WO2017079622A1
(en)
*
|
2015-11-04 |
2017-05-11 |
Emory University |
Immune cells with dnmt3a gene modifications and methods related thereto
|
WO2017087708A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
CA3004349A1
(en)
|
2015-11-23 |
2017-06-01 |
Sangamo Therapeutics, Inc. |
Methods and compositions for engineering immunity
|
US11479755B2
(en)
|
2015-12-07 |
2022-10-25 |
2Seventy Bio, Inc. |
T cell compositions
|
US11052111B2
(en)
|
2015-12-08 |
2021-07-06 |
Chimera Bioengineering, Inc. |
Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
|
IL297018A
(en)
|
2015-12-18 |
2022-12-01 |
Sangamo Therapeutics Inc |
Directed cleavage of cell mhc receptor
|
US11352631B2
(en)
|
2015-12-18 |
2022-06-07 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
PL3400246T3
(pl)
|
2016-01-08 |
2021-03-08 |
F. Hoffmann-La Roche Ag |
Sposoby leczenia nowotworów z dodatnim markerem cea z wykorzystaniem antagonistów wiążących oś pd-1 oraz przeciwciał dwuswoistych anty-cea/anty-cd3
|
KR102437015B1
(ko)
*
|
2016-04-15 |
2022-08-29 |
메모리얼 슬로안 케터링 캔서 센터 |
유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법
|
AU2017254477A1
(en)
|
2016-04-18 |
2018-11-01 |
Jennifer G. ABELIN |
Improved HLA epitope prediction
|
CN107304434A
(zh)
*
|
2016-04-25 |
2017-10-31 |
上海宇玫博生物科技有限公司 |
一种免疫细胞治疗的双功能新型载体
|
CN116254231A
(zh)
*
|
2016-04-25 |
2023-06-13 |
巴塞尔大学 |
等位基因编辑及其应用
|
US20220025001A1
(en)
*
|
2016-04-28 |
2022-01-27 |
The Trustees Of Dartmouth College |
Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
|
US11085035B2
(en)
|
2016-05-03 |
2021-08-10 |
Flodesign Sonics, Inc. |
Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
|
US11214789B2
(en)
|
2016-05-03 |
2022-01-04 |
Flodesign Sonics, Inc. |
Concentration and washing of particles with acoustics
|
MX2018013445A
(es)
*
|
2016-05-06 |
2019-09-09 |
Juno Therapeutics Inc |
Celulas diseñadas geneticamente y metodos para obtener las mismas.
|
WO2017201019A1
(en)
|
2016-05-17 |
2017-11-23 |
Chimera Bioengineering, Inc. |
Methods for making novel antigen binding domains
|
CA3026180A1
(en)
|
2016-06-10 |
2017-12-14 |
Gadeta B.V. |
Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
|
GB2568182A
(en)
|
2016-08-03 |
2019-05-08 |
Harvard College |
Adenosine nucleobase editors and uses thereof
|
AU2017308889B2
(en)
|
2016-08-09 |
2023-11-09 |
President And Fellows Of Harvard College |
Programmable Cas9-recombinase fusion proteins and uses thereof
|
KR20180018457A
(ko)
*
|
2016-08-12 |
2018-02-21 |
주식회사 툴젠 |
조작된 면역조절요소 및 이에 의해 변형된 면역 활성
|
CN109844118A
(zh)
*
|
2016-08-12 |
2019-06-04 |
株式会社图尔金 |
经操纵的免疫调节因子以及由此改变的免疫力
|
IL264439B1
(en)
|
2016-08-17 |
2024-04-01 |
Factor Bioscience Inc |
A suitable viral preparation containing a synthetic messenger RNA encoding a gene editing protein for use in cancer treatment and a synthetic messenger RNA encoding a gene editing protein for use in therapy
|
US11630103B2
(en)
|
2016-08-17 |
2023-04-18 |
The Broad Institute, Inc. |
Product and methods useful for modulating and evaluating immune responses
|
BR112019003327A2
(pt)
|
2016-08-24 |
2019-07-02 |
Sangamo Therapeutics Inc |
nucleases manipuladas de alvo específico
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
CN112481217A
(zh)
|
2016-09-01 |
2021-03-12 |
嵌合体生物工程公司 |
Gold优化的car t-细胞
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
RU2019106216A
(ru)
*
|
2016-09-12 |
2020-10-12 |
Эксижн Биотерапьютикс Инк |
Клинический протокол для вич
|
EA201990591A1
(ru)
|
2016-09-23 |
2019-08-30 |
Фред Хатчинсон Кэнсер Рисерч Сентер |
Tcr, специфичные к минорному антигену гистосовместимости (h) ha-1, и их применения
|
CN110036033B
(zh)
|
2016-09-27 |
2023-12-08 |
森罗治疗公司 |
嵌合吞噬受体分子
|
WO2018067826A1
(en)
|
2016-10-05 |
2018-04-12 |
Cellular Dynamics International, Inc. |
Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
MA46649A
(fr)
|
2016-10-13 |
2019-08-21 |
Juno Therapeutics Inc |
Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane
|
KR102622411B1
(ko)
|
2016-10-14 |
2024-01-10 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
CN110520530A
(zh)
*
|
2016-10-18 |
2019-11-29 |
明尼苏达大学董事会 |
肿瘤浸润性淋巴细胞和治疗方法
|
JP2020513248A
(ja)
|
2016-10-19 |
2020-05-14 |
フロデザイン ソニックス, インク.Flodesign Sonics, Inc. |
音響による親和性細胞抽出
|
CN110022904B
(zh)
|
2016-10-20 |
2024-04-19 |
桑格摩生物治疗股份有限公司 |
用于治疗法布里病的方法和组合物
|
AU2017347854B2
(en)
*
|
2016-10-27 |
2022-12-08 |
Intima Bioscience, Inc. |
Viral methods of T cell therapy
|
US11440958B2
(en)
|
2016-11-22 |
2022-09-13 |
National University Of Singapore |
Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
|
CN110494565A
(zh)
|
2016-12-02 |
2019-11-22 |
朱诺治疗学股份有限公司 |
工程化b细胞及相关组合物和方法
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
US11555178B2
(en)
|
2017-01-18 |
2023-01-17 |
Yeda Research And Development Co. Ltd. |
Genetically modified veto cells and use of same in immunotherapy
|
US10751368B2
(en)
|
2017-01-18 |
2020-08-25 |
Yeda Research And Development Co. Ltd. |
Methods of transplantation and disease treatment
|
EP3574116A1
(en)
|
2017-01-24 |
2019-12-04 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
US20190381157A1
(en)
*
|
2017-01-29 |
2019-12-19 |
Zequn Tang |
Methods of immune modulation against foreign and/or auto antigens
|
CN110612119A
(zh)
|
2017-02-07 |
2019-12-24 |
西雅图儿童医院(Dba西雅图儿童研究所) |
磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
|
EP3589295A4
(en)
|
2017-02-28 |
2020-11-04 |
Endocyte, Inc. |
COMPOSITIONS AND METHODS OF T CAR LYMPHOCYTE THERAPY
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
WO2018165629A1
(en)
|
2017-03-10 |
2018-09-13 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
SG11201908527SA
(en)
|
2017-03-15 |
2019-10-30 |
Hutchinson Fred Cancer Res |
High affinity mage-a1-specific tcrs and uses thereof
|
RU2019133280A
(ru)
|
2017-03-22 |
2021-04-22 |
Новартис Аг |
Композиции и способы для иммуноонкологии
|
EP3601562A1
(en)
|
2017-03-23 |
2020-02-05 |
President and Fellows of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
EP3606518A4
(en)
|
2017-04-01 |
2021-04-07 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
|
EP3610266A4
(en)
|
2017-04-12 |
2021-04-21 |
Massachusetts Eye and Ear Infirmary |
TUMOR SIGNATURE OF METASTASIS, COMPOSITIONS OF SUBSTANCES AND USES THEREOF
|
KR20240059648A
(ko)
|
2017-04-19 |
2024-05-07 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
조작된 항원 수용체를 발현하는 면역 세포
|
WO2018200943A1
(en)
|
2017-04-28 |
2018-11-01 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
AU2018264636B2
(en)
*
|
2017-05-08 |
2022-03-17 |
Toolgen Incorporated |
Artificially manipulated immune cell
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
MX2019013514A
(es)
*
|
2017-05-12 |
2020-01-20 |
Crispr Therapeutics Ag |
Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
|
US10780119B2
(en)
|
2017-05-24 |
2020-09-22 |
Effector Therapeutics Inc. |
Methods and compositions for cellular immunotherapy
|
EP3638218A4
(en)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
CN114350613A
(zh)
|
2017-06-20 |
2022-04-15 |
居里研究所 |
Suv39h1缺陷的免疫细胞
|
WO2019006418A2
(en)
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
CA3068203A1
(en)
|
2017-07-14 |
2019-01-17 |
The Francis Crick Institute Limited |
Analysis of hla alleles in tumours and the uses thereof
|
US11732274B2
(en)
|
2017-07-28 |
2023-08-22 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
|
US11648269B2
(en)
|
2017-08-10 |
2023-05-16 |
National University Of Singapore |
T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
|
EP3676376A2
(en)
|
2017-08-30 |
2020-07-08 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
JP2020535128A
(ja)
|
2017-09-19 |
2020-12-03 |
マサチューセッツ インスティテュート オブ テクノロジー |
キメラ抗原受容体t細胞治療のための組成物およびその使用
|
KR20200066616A
(ko)
|
2017-09-21 |
2020-06-10 |
더 브로드 인스티튜트, 인코퍼레이티드 |
표적화된 핵산 편집을 위한 시스템, 방법 및 조성물
|
KR20200100598A
(ko)
|
2017-09-26 |
2020-08-26 |
세로 테라퓨틱스, 인코포레이티드 |
키메라 포식작용 수용체 분자 및 사용 방법
|
WO2019061324A1
(en)
|
2017-09-29 |
2019-04-04 |
Curis Inc. |
CRYSTALLINE FORMS OF IMMUNOMODULATORS
|
EP3694841A1
(en)
|
2017-10-11 |
2020-08-19 |
Aurigene Discovery Technologies Limited |
Crystalline forms of 3-substituted 1,2,4-oxadiazole
|
KR20200121782A
(ko)
|
2017-10-16 |
2020-10-26 |
더 브로드 인스티튜트, 인코퍼레이티드 |
아데노신 염기 편집제의 용도
|
KR20200083503A
(ko)
|
2017-11-03 |
2020-07-08 |
오리진 디스커버리 테크놀로지스 리미티드 |
Tim-3 경로와 pd-1 경로의 이중 저해제
|
CN111386128A
(zh)
|
2017-11-06 |
2020-07-07 |
奥瑞基尼探索技术有限公司 |
用于免疫调节的联合疗法
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
US11738047B2
(en)
*
|
2017-12-12 |
2023-08-29 |
The Trustees Of The University Of Pennsylvania |
Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
|
CA3085784A1
(en)
|
2017-12-14 |
2019-06-20 |
Flodesign Sonics, Inc. |
Acoustic transducer driver and controller
|
US20210002621A1
(en)
*
|
2017-12-20 |
2021-01-07 |
Bluebird Bio, Inc. |
Ctla4 homing endonuclease variants, compositions, and methods of use
|
AU2019209428A1
(en)
|
2018-01-22 |
2020-07-30 |
Endocyte, Inc. |
Methods of use for CAR T cells
|
EP3806870A4
(en)
|
2018-02-13 |
2021-12-22 |
Chimera Bioengineering, Inc. |
COORDINATION OF GENE EXPRESSION USING RNA DESTABILIZING ELEMENTS
|
CN112041432A
(zh)
|
2018-02-15 |
2020-12-04 |
纪念斯隆-凯特林癌症中心 |
Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
|
EP3765094A4
(en)
|
2018-03-15 |
2021-12-22 |
KSQ Therapeutics, Inc. |
GENE REGULATION COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY
|
US20210024607A1
(en)
|
2018-03-28 |
2021-01-28 |
Cero Therapeutics, Inc. |
Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
|
WO2019191332A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
|
US20210087251A1
(en)
|
2018-03-28 |
2021-03-25 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
EP3775238A1
(en)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics, Inc. |
Methods of producing cells expressing a recombinant receptor and related compositions
|
CA3095084A1
(en)
|
2018-04-05 |
2019-10-10 |
Juno Therapeutics, Inc. |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
CN112771080A
(zh)
*
|
2018-07-18 |
2021-05-07 |
美国安进公司 |
针对steap1的嵌合受体及其使用方法
|
US20210177832A1
(en)
|
2018-08-20 |
2021-06-17 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease target binding and uses thereof
|
WO2020041387A1
(en)
|
2018-08-20 |
2020-02-27 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
WO2020041384A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
|
CN113015741A
(zh)
*
|
2018-09-18 |
2021-06-22 |
桑格摩生物治疗股份有限公司 |
程序性细胞死亡1(pd1)特异性核酸酶
|
BR112021004383A2
(pt)
|
2018-09-28 |
2021-08-03 |
Massachusetts Institute Of Technology |
proteína de fusão imunomoduladora, composição farmacêutica, ácido nucleico, vetor de expressão, célula transformada, método para a produção de uma proteína de fusão imunomoduladora, método para ativar, aumentar ou promover uma resposta por uma célula imune em um sujeito, método para inibir, reduzir ou suprimir uma resposta por uma célula imune em um sujeito, método para reduzir ou inibir o crescimento do tumor, método para tratar câncer em um sujeito, kit, uso de uma proteína de fusão imunomoduladora e método para reduzir ou inibir o crescimento do tumor ou tratar o câncer em um sujeito
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
EP3887518A2
(en)
*
|
2018-11-28 |
2021-10-06 |
Board of Regents, The University of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
KR20210096648A
(ko)
|
2018-11-29 |
2021-08-05 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
자연 살해 세포의 생체외 확장을 위한 방법 및 이의 용도
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
AU2020205717A1
(en)
|
2019-01-11 |
2021-08-12 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
BR112021018606A2
(pt)
|
2019-03-19 |
2021-11-23 |
Harvard College |
Métodos e composições para editar sequências de nucleotídeos
|
BR112021021075A2
(pt)
|
2019-05-01 |
2021-12-14 |
Editas Medicine Inc |
Células que expressam um receptor recombinante de um locus de tgfbr2 modificado, polinucleotídeos relacionados e métodos
|
BR112021021200A2
(pt)
|
2019-05-01 |
2021-12-21 |
Juno Therapeutics Inc |
Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
KR20220010738A
(ko)
|
2019-05-21 |
2022-01-26 |
상가모 테라퓨틱스, 인코포레이티드 |
조절 t 세포에서 제어된 트랜스진 발현
|
US20220226464A1
(en)
|
2019-05-28 |
2022-07-21 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
US11642409B2
(en)
|
2019-06-26 |
2023-05-09 |
Massachusetts Insttute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
CN114222815A
(zh)
|
2019-07-23 |
2022-03-22 |
记忆疗法公司 |
Suv39h1缺陷的免疫细胞
|
US10501404B1
(en)
|
2019-07-30 |
2019-12-10 |
Factor Bioscience Inc. |
Cationic lipids and transfection methods
|
GB201911066D0
(en)
|
2019-08-02 |
2019-09-18 |
Achilles Therapeutics Ltd |
T cell therapy
|
WO2021026336A2
(en)
*
|
2019-08-07 |
2021-02-11 |
I Altius Institute For Biomedical Sciences |
Compositions and methods for modulation of gene expression
|
WO2021028359A1
(en)
|
2019-08-09 |
2021-02-18 |
Sangamo Therapeutics France |
Controlled expression of chimeric antigen receptors in t cells
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
EP4013431A4
(en)
|
2019-08-18 |
2024-05-01 |
Chimera Bioengineering Inc |
COMBINATION THERAPY WITH GOLD-CONTROLLED TRANSGENES
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
BR112022003790A2
(pt)
|
2019-09-02 |
2022-05-31 |
Inst Nat Sante Rech Med |
Método para selecionar um peptídeo neoantigênico tumoral, peptídeos neoantigênicos tumorais, peptídeo neoantigênico tumoral isolado, população de células dendríticas autólogas, vacina ou composição imunogênica, anticorpos, método de produção de um anticorpo, receptor de células t, polinucleotídeo, vetor, célula imune, célula t, peptídeo neoantigênico e população de células imunes
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
WO2021067875A1
(en)
|
2019-10-03 |
2021-04-08 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
EP4048304A1
(en)
|
2019-10-22 |
2022-08-31 |
Institut Curie |
Immunotherapy targeting tumor neoantigenic peptides
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
GB201918290D0
(en)
|
2019-12-12 |
2020-01-29 |
Achilles Therapeutics Ltd |
Method
|
WO2021116714A1
(en)
|
2019-12-12 |
2021-06-17 |
Achilles Therapeutics Uk Limited |
Method for obtaining nucleic acid for sequencing
|
US11865168B2
(en)
|
2019-12-30 |
2024-01-09 |
Massachusetts Institute Of Technology |
Compositions and methods for treating bacterial infections
|
US20230183377A1
(en)
|
2020-02-26 |
2023-06-15 |
Sorrento Therapeutics, Inc. |
Activatable antigen binding proteins with universal masking moieties
|
WO2021183675A2
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Methods for generating engineered memory-like nk cells and compositions thereof
|
WO2021183207A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF NPM1c-POSITIVE CANCER
|
WO2021217083A1
(en)
|
2020-04-24 |
2021-10-28 |
Sorrento Therapeutics, Inc. |
Memory dimeric antigen receptors
|
IL297594A
(en)
|
2020-04-28 |
2022-12-01 |
Achilles Therapeutics Uk Ltd |
t cell therapy
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
US20210338833A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
DE112021002672T5
(de)
|
2020-05-08 |
2023-04-13 |
President And Fellows Of Harvard College |
Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
|
EP4149952A1
(en)
|
2020-05-12 |
2023-03-22 |
Institut Curie |
Neoantigenic epitopes associated with sf3b1 mutations
|
KR20230022868A
(ko)
|
2020-05-13 |
2023-02-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
|
JP2023528293A
(ja)
|
2020-05-20 |
2023-07-04 |
アンスティテュ・クリー |
単一ドメイン抗体及びがん治療におけるその使用
|
EP4171616A1
(en)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
AU2021308681A1
(en)
|
2020-07-16 |
2023-03-09 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
JP2023535501A
(ja)
|
2020-07-30 |
2023-08-17 |
アンスティテュ・クリー |
Socs1に欠陥のある免疫細胞
|
WO2022036265A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim receptors and uses thereof
|
WO2022036285A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
|
WO2022036287A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Anti-cd72 chimeric receptors and uses thereof
|
EP4229090A1
(en)
|
2020-10-16 |
2023-08-23 |
Université d'Aix-Marseille |
Anti-gpc4 single domain antibodies
|
US20230398148A1
(en)
|
2020-11-04 |
2023-12-14 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
US20220162288A1
(en)
|
2020-11-25 |
2022-05-26 |
Catamaran Bio, Inc. |
Cellular therapeutics engineered with signal modulators and methods of use thereof
|
WO2022118310A1
(en)
*
|
2020-12-01 |
2022-06-09 |
Lepton Pharmaceuticals Ltd. |
Methods for enhancing therapeutic efficacy of isolated cells for cell therapy
|
IL304031A
(en)
|
2021-01-14 |
2023-08-01 |
Inst Curie |
Variants of single-domain HER2 antibodies and their chimeric antigenic receptors
|
WO2022189626A2
(en)
|
2021-03-11 |
2022-09-15 |
Mnemo Therapeutics |
Tumor neoantigenic peptides
|
CA3213002A1
(en)
|
2021-03-11 |
2022-09-15 |
Institut Curie |
Transmembrane neoantigenic peptides
|
CA3213004A1
(en)
|
2021-03-11 |
2022-09-15 |
Mnemo Therapeutics |
Tumor neoantigenic peptides and uses thereof
|
EP4320435A1
(en)
|
2021-04-09 |
2024-02-14 |
Achilles Therapeutics UK Limited |
Batch release assay for pharmaceutical products relating to t cell therapies
|
GB202109886D0
(en)
|
2021-07-08 |
2021-08-25 |
Achilles Therapeutics Uk Ltd |
Assay
|
KR20240023426A
(ko)
|
2021-06-22 |
2024-02-21 |
아킬레스 테라퓨틱스 유케이 리미티드 |
항원-특이적 t 세포를 생산하는 방법
|
WO2023010097A1
(en)
|
2021-07-28 |
2023-02-02 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
WO2023014922A1
(en)
|
2021-08-04 |
2023-02-09 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
WO2023114887A2
(en)
*
|
2021-12-15 |
2023-06-22 |
The Trustees Of Indiana University |
Cell targeting compositions and methods
|
WO2023126458A1
(en)
|
2021-12-28 |
2023-07-06 |
Mnemo Therapeutics |
Immune cells with inactivated suv39h1 and modified tcr
|
WO2023180552A1
(en)
|
2022-03-24 |
2023-09-28 |
Institut Curie |
Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
|
EP4279085A1
(en)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
|
GB202210006D0
(en)
|
2022-07-07 |
2022-08-24 |
Achilles Therapeutics Uk Ltd |
Analysis of T cell samples
|
WO2024062138A1
(en)
|
2022-09-23 |
2024-03-28 |
Mnemo Therapeutics |
Immune cells comprising a modified suv39h1 gene
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|